Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
Public ClinicalTrials.gov record NCT01496430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.
Study identification
- NCT ID
- NCT01496430
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2012 (Type not available)
- Primary completion
- May 2013 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- May 6, 2015
2012 – 2013
United States locations
- U.S. sites
- 68
- U.S. states
- 27
- U.S. cities
- 68
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Green Valley | Arizona | — | — |
| Not listed | Tempe | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Buena Park | California | — | — |
| Not listed | Hawaiian Gardens | California | — | — |
| Not listed | Norwalk | California | — | — |
| Not listed | Paramount | California | — | — |
| Not listed | Rancho Cucamonga | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Brooksville | Florida | — | — |
| Not listed | Hallandale | Florida | — | — |
| Not listed | Jupiter | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Roswell | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Evergreen Park | Illinois | — | — |
| Not listed | Gurnee | Illinois | — | — |
| Not listed | Avon | Indiana | — | — |
| Not listed | Greenfield | Indiana | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Margate City | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Calabash | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Lenoir | North Carolina | — | — |
| Not listed | Morehead City | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Centerville | Ohio | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Downingtown | Pennsylvania | — | — |
| Not listed | Fleetwood | Pennsylvania | — | — |
| Not listed | Reading | Pennsylvania | — | — |
| Not listed | Providence | Rhode Island | — | — |
| Not listed | Anderson | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | North Richland Hills | Texas | — | — |
| Not listed | Pearland | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burke | Virginia | — | — |
| Not listed | Manassas | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Virginia Beach | Virginia | — | — |
| Not listed | Wauwatosa | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01496430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2015 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01496430 live on ClinicalTrials.gov.